X

Trial Profile

Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mepolizumab (Primary)
Indications Asthma
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

28 Sep 2012 Accrual to date is 90% as reported by United Kingdom Clinical Research Network.
20 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
08 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com